U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes
Only prescription medication in U.S.
Editor Note: For more information about this release, please scroll to bottom.
LONDON, February 2, 2015
Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) Becomes First and Only Treatment Approved by the FDA for Adults with Moderate to Severe Binge Eating Disorder
Merck Repatriates Diabetes and Thyroids Portfolio in Russia to Continue to Drive Emerging Markets Strategy
PREZCOBIX(TM) (darunavir/cobicistat) Approved in the U.S. for the Treatment of Adults Living With HIV-1
Theravance Biopharma, Inc. and Mylan Partner to Develop and Commercialize a Novel LAMA Compound, TD-4208, for COPD
Valeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T)
VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity
Amgen, The Familial Hypercholesterolemia Foundation And Stanford Medicine Launch FIND FH™ Initiative To Improve Diagnosis And Care For People With Familial Hypercholesterolemia
FIND FH Initiative Unites Industry, Advocacy Community and Academia in an Effort to Support People Affected by Familial Hypercholesterolemia (FH), a Serious Genetic Disorder
- Fourth-Quarter EPS Above Previous Guidance Range, Including Results From Discontinued Operations -
ABBOTT PARK, Ill., Jan.